METABOLIC, REPRODUCTIVE OUTCOMES AND SIDE EFFECTS AFTER THE ADMINISTRATION OF 100 MG DEHYDROEPIANDROSTERONE (DHEA) IN WOMEN WITH AN ADEQUATE OVARIAN RESERVE

Abstract

Describe the metabolic, reproductive outcomes and side effects after the administration of 100 mg DHEA in women with an adequate ovarian reserve Self-controlled study of 27 women (29 to 45 years old), with an adequate ovarian reserve according to the POSEIDON criteria. During the period from February 2020 to September 2020. Participants were administered 100 mg of DHEA daily for 16 weeks and the metabolic (clinical and biochemical), reproductive (clinical, ultrasound and biochemical) outcomes and side effects were evaluated. We define clinical metabolic results as body mass index, abdominal circumference, mean arterial pressure, and the Ferriman Gallwey scale, while biochemical results are levels of hematocrit, glucose, insulin, HOMA index, triglycerides, total, HDL, LDL cholesterol and microalbuminuria. The clinical reproductive results were the frequency and duration of the menstrual cycle and ultrasound scans to the antral follicular count, ovarian volume and endometrial line. And finally, the biochemicals to the follicle-stimulating, luteinizing, estradiol and anti-Müllerian hormones. The adverse effects were determined by the presence of allergies, mastalgia, mammary nodules, ovarian tumors, acne and hair loss. All participants had a history of at least one pregnancy and were using a non-hormonal contraceptive method. The average age of the women studied was 35.88 ± 3.80. For clinical and biochemical metabolic outcomes, there was no statistically significant difference compared to baseline measurement. The frequency and duration of the menstrual cycle during the four months remained without significant changes compared to baseline, as well as the ultrasonographic characteristics. Difference was found in the antral follicular count from the 3rd (14.61 ± 2.07) and 4th (14.57 ± 2.08) months compared with the baseline measurement (11.51 ± 3.93, p <0.001). The levels of follicle stimulating hormone, luteinizing and estradiol during the four months were maintained without significant changes compared to baseline. A difference was found in anti-Müllerian hormone levels from the 3rd (2.03 ± 0.43) month compared to the baseline (1.50 ± 0.36, p <0.001). In only one case the presence of acne appeared from the second month (3.70%, p = 0.40). When studying only the age group older than 34 years, it was found that the antral follicular count improved from the second month (13.24 ± 2.16, p = 0.03), the third month (14.56 ± 2, 16, p <0.01), fourth month (14.25 ± 2.14, p<0.01) with a baseline (10.65 ± 3.52). And the anti Müllerian hormone improved from the third month (2.03 ± 0.41, p <0.01), fourth month (2.15 ± 0.32, p <0.01) with a baseline (1, 49 ± 0.36). In the population studied, the administration of 100mg of DHEA per day for 16 weeks. There was no modification in the metabolic and reproductive variables, uncommon side effects and the adequate ovarian reserve is maintained.